Mark J Ahn

Mark J. Ahn, Ph.D. is President, Chief Executive Officer, and Director of RXi Pharmaceuticals. Prior to RXi, Mark was Principal at Pukana Partners, Ltd. that provides strategic consulting to life science companies; and Associate Professor, Global Management at Atkinson Graduate School of Management, Willamette University. He previously served as Chair, Science & Technology Management, Victoria University at Wellington, New Zealand. Mark was also founder, President, and Chief Executive Officer of Hana Biosciences. Prior to Hana, he served as Vice President, Hematology and corporate officer at Genentech, Inc., as well as held positions of increasing responsibility at Amgen and Bristol-Myers Squibb Company; and served in the US Army. Mark also serves on public and venture capital-backed Board of Directors for Access Pharmaceuticals, Mesynthes and Scribes STAT. He is the author of over 50 peer reviewed journal articles and books including Making the Case for Biotechnology (Logos Press). Mark received a BA and MBA from Chaminade University; and MA from Victoria University. He was a graduate fellow in Economics at Essex University, and obtained a Ph.D. from the University of South Australia. He is a Henry Crown Fellow at the Aspen Institute class of 2001.